Explore Stanford technologies available for licensing:

Researchers at Stanford have discovered a new cellular target for treating chronic pain caused by injury or surgery, opening the door to a potential new class of non-addictive pain medications.

Stanford researchers have developed a human spleen organoid platform that models inflammation and autoimmune responses to bacterial peptidoglycans in a physiologically relevant human immune setting.

Systemic chemotherapy remains the main treatment option for malignant tumors, including breast cancer. Nevertheless, the frequent development of resistance in tumors often causes treatment failure and patient death, presenting a significant challenge in cancer treatment.

Stanford researchers have developed novel AsCas12a-expressing mouse models for simultaneous editing of multiple genomic loci in vivo with unique targeting capabilities relative to traditional Cas9 models, enabling the rapid creation of complex genotypes in somatic cells and ca

Stanford researchers have designed a electrochemical sensor system for continuous analyte measurement and tracking in complex biological samples (i.e. blood and serum) with a wide range of clinical and non clinical applications.

Stanford scientists have developed a lateral flow diagnostic platform that detects pathogen DNA without nucleic acid amplification, delivering results visible to the naked eye in under 30 minutes.

Researchers from Stanford developed recombinant polypeptide-cytokine conjugates and methods to induce antigen-specific regulatory T cells (Treg) for the treatment of inflammatory and autoimmune diseases.

Stanford researchers have developed recombinant polypeptides targeting growth factor beta (TGF-?) receptor 1 and TGF?

Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.

Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.

Stanford researchers have developed a novel PET agent for diseases stemming from T cell origin. The probes help visualize the disease status as well as the progress of therapy.

Stanford scientists have developed a method and apparatus for simultaneously measuring mucus rheology and cilia activity on live airway cells without removing mucus or inhibiting cilia function.

The blood-brain barrier (BBB) remains a major obstacle to developing effective therapies for neurological and neurodegenerative disease, because most drugs and biologics do not efficiently reach brain tissue.

Scientists at Stanford have developed a new method to manufacture sterile microbial food that contains levels of key bioactive metabolites derived from fermented foods.

Stanford scientists have discovered that theta oscillations in the anterior cingulate cortex can detect empathic states, and that targeting the upstream orexin circuit can modulate empathy-related behaviors.